Batu Biologics Files Patent Covering Its Proprietary Cancer Vaccine Targeting The Tumor Endothelium: Vallovax
5/27/2014 8:25:28 AM
SAN DIEGO--(BUSINESS WIRE)--Batu Biologics, a biopharmaceutical company focused on the development and commercialization of cell therapies in the area of immune modulation, is pleased to announce the filing of U.S. patent application (61/987657) covering the composition and application of its flagship product, Vallovax. The novel cancer vaccine is specifically formulated to target the blood vessels that supply the tumor through induction of tumor autoimmunity and immune stimulation.
Help employers find you! Check out all the jobs and post your resume.
comments powered by